Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and ...
Panelists discuss how successfully integrating subcutaneous (SubQ) therapies into oncology practice depends on comprehensive education, optimized workflows, transparent patient communication, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results